Biblio
] , “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease.”, J Alzheimers Dis, vol. 67, no. 2, pp. 555-570, 2019.
, “Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer's Disease Hippocampus.”, J Alzheimers Dis, vol. 63, no. 3, pp. 1173-1189, 2018.
, “Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer's Disease Phase IIa and Expanded Access Trials.”, J Alzheimers Dis, vol. 58, no. 2, pp. 521-535, 2017.
